Biopharma innovation is moving fast, yet according to Ryan Keeling, CEO of Diaceutics, the industry continues to face a fundamental challenge: too many eligible patients never reach the therapies developed for them. The problem is ensuring patients are identified, diagnosed and guided successfully through increasingly complex care pathways.
In this conversation, Keeling points out that healthcare has historically focused commercialization efforts on the moment a treatment decision is made. For diagnostic-driven therapies (therapies where diagnostic activity heavily influences whether, when, or how a patient reaches treatment), that approach is no longer sufficient. He makes the case for focusing on the entire patient pathway, from testing and diagnosis through treatment selection, to better understand where patients are lost and how those barriers can be addressed in real time.
The discussion also explores Diaceutics' vision of "Precision for All," an industry-wide ambition to ensure every eligible patient is identified, diagnosed and receives the right therapy at the right time. Keeling outlines why a more prospective (not retrospective), data-driven approach to patient identification and diagnosis could help close the gap between scientific innovation and real-world patient outcomes.
Watch the interview to hear Keeling's perspective on the future of diagnostic-driven therapy commercialization.